Synthetic retinoid fenretinide in breast cancer chemoprevention

Research output: Contribution to journalArticle

Abstract

Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.

Original languageEnglish
Pages (from-to)423-432
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume7
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Fenretinide
Retinoids
Chemoprevention
Breast Neoplasms
Breast
Second Primary Neoplasms
Primary Prevention
Toxicology
Action Potentials
Carcinogenesis
Clinical Trials
Apoptosis
Incidence
Research

Keywords

  • Breast neoplasm
  • Chemoprevention
  • Clinical trial
  • Fenretinide
  • Retinoid

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Synthetic retinoid fenretinide in breast cancer chemoprevention. / Bonanni, Bernardo; Lazzeroni, Matteo; Veronesi, Umberto.

In: Expert Review of Anticancer Therapy, Vol. 7, No. 4, 04.2007, p. 423-432.

Research output: Contribution to journalArticle

@article{6a10839a53eb463f8c06ca782a9ef96b,
title = "Synthetic retinoid fenretinide in breast cancer chemoprevention",
abstract = "Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.",
keywords = "Breast neoplasm, Chemoprevention, Clinical trial, Fenretinide, Retinoid",
author = "Bernardo Bonanni and Matteo Lazzeroni and Umberto Veronesi",
year = "2007",
month = "4",
doi = "10.1586/14737140.7.4.423",
language = "English",
volume = "7",
pages = "423--432",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Synthetic retinoid fenretinide in breast cancer chemoprevention

AU - Bonanni, Bernardo

AU - Lazzeroni, Matteo

AU - Veronesi, Umberto

PY - 2007/4

Y1 - 2007/4

N2 - Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.

AB - Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.

KW - Breast neoplasm

KW - Chemoprevention

KW - Clinical trial

KW - Fenretinide

KW - Retinoid

UR - http://www.scopus.com/inward/record.url?scp=34247559202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247559202&partnerID=8YFLogxK

U2 - 10.1586/14737140.7.4.423

DO - 10.1586/14737140.7.4.423

M3 - Article

C2 - 17428163

AN - SCOPUS:34247559202

VL - 7

SP - 423

EP - 432

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 4

ER -